Xencor, Inc. (XNCR) Q1 2026 10-Q Summary
Business Context and Reporting Period
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on engineered antibody therapeutics for cancer and autoimmune diseases. This report covers the quarterly period ended March 31, 2026. The company operates as a single reportable segment and relies on collaboration revenues, milestone payments, and royalties, alongside significant internal research and development (R&D) expenditures.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $4.5 million | $32.7 million |
| Net Loss | $(128.9) million | $(48.4) million |
| Operating Loss | $(77.9) million | $(43.2) million |
| R&D Expenses | $64.7 million | $58.6 million |
| Net Cash Used in Operating Activities | $(67.6) million | $(16.2) million |
| Cash, Cash Equivalents, and Marketable Securities | $541.8 million | $610.8 million (Dec 31, 2025) |
| Liabilities Related to Future Royalty Sales | $108.5 million | $119.7 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $28.2 million (86%) compared to Q1 2025. This was primarily driven by a $6.6 million reduction in royalty revenue from Alexion due to a dispute over U.S. sales royalties and the absence of significant milestone payments recognized in the prior year.
- Net Loss Expansion: Net loss increased by $80.5 million. The widening loss was significantly impacted by a $51.9 million unrealized loss on marketable equity securities (specifically the investment in Zenas BioPharma), compared to a $0.9 million gain in the prior year.
- R&D Increase: R&D expenses rose by $6.1 million, driven by increased external and internal costs for key programs including XmAb819, XmAb942, and XmAb412, partially offset by lower stock-based compensation.
- Liquidity: Cash and cash equivalents decreased by approximately $40 million during the quarter, primarily due to operating cash outflows and net investment activity.
Guidance, Outlook, and Risks
- Outlook: Management believes current financial resources are sufficient to fund operations through at least the next twelve months and potentially into 2028, assuming current operating plans hold. The company filed a shelf registration statement (Form S-3) in February 2026 to facilitate future capital raises.
- Alexion Dispute: A material contingency exists regarding royalties from Alexion (Ultomiris). Alexion notified Xencor in March 2026 that it does not intend to make future U.S. royalty payments. Xencor disputes this and has constrained U.S. royalty revenue to zero pending resolution. The ultimate recovery amount and timing are uncertain.
- Legal Proceedings: Xencor is involved in patent litigation with Merus N.V. regarding common light chain antibodies. While the court granted a motion to dismiss the initial complaint, Merus filed an amended complaint. Xencor believes it has strong defenses but notes the outcome is uncertain.
- Investment Volatility: The company holds significant marketable equity securities (Zenas BioPharma), which contributed to a substantial unrealized loss in the quarter. Future fluctuations in the fair value of these securities could materially impact reported earnings.
Investor Verification Checklist
- Alexion Royalty Dispute: Verify the status of the legal or commercial resolution regarding the $6.6 million constrained revenue and potential future U.S. royalty exposure.
- Zenas BioPharma Investment: Monitor the fair value of the Zenas equity stake, as unrealized gains/losses significantly distort operating performance metrics.
- Cash Burn Rate: Assess the sustainability of the ~$67.6 million quarterly operating cash burn against the $541.8 million liquidity position.
- R&D Pipeline Progress: Review clinical trial updates for key assets (XmAb819, XmAb942, XmAb541) to validate the continued increase in R&D spending.
- Merus Litigation: Track the outcome of the ongoing motion to dismiss the amended complaint filed by Merus.